AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26255520 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Zhibian (BL 54) through Shuidao (ST 28)
Number of subjects: 101
Study 26255520 — intervention group
Group type: COMPARATOR
Intervention: Regular acupuncture technique
Number of subjects: 101
Study 23334268 — intervention group
Group type: EXPERIMENTAL
Intervention: Local administration of piperacillin/tazobactam
Number of subjects: 36
Study 23334268 — intervention group
Group type: COMPARATOR
Intervention: Debridement alone
Number of subjects: 36
Study 22152494 — intervention group
Group type: EXPERIMENTAL
Intervention: F-YOP (yoghurt pack)
Number of subjects: 3
Study 22152494 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study 19437211 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato sauce meal (tomato sauce, rice and olive oil)
Number of subjects: 10
Study 19437211 — intervention group
Group type: COMPARATOR
Intervention: Placebo meal (rice and olive oil)
Number of subjects: 10
Study 16428532 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 38
Study 16428532 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 38
Study 14760442 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium swallow approach for determining septal puncture site
Number of subjects: 84
Study 14760442 — intervention group
Group type: COMPARATOR
Intervention: Normal fluoroscopic view for determining septal puncture site
Number of subjects: 84
Study 10768702 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent vouchers for opiate-negative urine specimens (n = 29 patients)
Number of subjects: 120
Study 10768702 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone hydrochloride dose increase to 70 mg/d (n = 31 patients)
Number of subjects: 120
Study 10768702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined contingent vouchers and methadone dose increase (n = 32 patients)
Number of subjects: 120
Study 10768702 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (comparison standard; n = 28 patients)
Number of subjects: 120
Study 8808718 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg once daily for 15 days
Number of subjects: 294
Study 8808718 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily for 15 days
Number of subjects: 294
Study 1425877 — intervention group
Group type: EXPERIMENTAL
Intervention: nalbuphine (0.2 mg.kg‐1 i.v.)
Number of subjects: 10
Study 1425877 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 4016785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose treatment strategy (2 X 10(6) units/m2 daily for 28 days, then daily for 5 days every other week by im injection)
Number of subjects: 0
Study 4016785 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose treatment strategy (5 X 10(6) units/m2 by continuous iv infusion over 24 hours, escalating by 5 X 10(6) units/m2/day as tolerated over 10 days, repeated every 28 days)
Number of subjects: 0
Study 30927922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastrach
Number of subjects: 80
Study 30927922 — intervention group
Group type: COMPARATOR
Intervention: Ambu Aura‐i
Number of subjects: 80
Study 30927922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 80
Study 31156013 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure action plan + standard care
Number of subjects: 102
Study 31156013 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 102
Study 27796466 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide 1 mg
Number of subjects: 48
Study 27796466 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide 5 mg
Number of subjects: 48
Study 27796466 — intervention group
Group type: EXPERIMENTAL
Intervention: Netazepide 25 mg
Number of subjects: 48
Study 27796466 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg daily for 28 days
Number of subjects: 48
Study 27796466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 25997746 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 139
Study 25997746 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 139
Study 25997746 — intervention group
Group type: EXPERIMENTAL
Intervention: Different TNFi
Number of subjects: 139
Study 23446906 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) breakfast (350-kcal, 35 g protein)
Number of subjects: 20
Study 23446906 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-protein (NP) breakfast (350-kcal, 13 g protein)
Number of subjects: 20
Study 23446906 — intervention group
Group type: COMPARATOR
Intervention: Breakfast skipping (BS)
Number of subjects: 20
Study 21794128 — intervention group
Group type: COMPARATOR
Intervention: Attention Network Test (ANT)
Number of subjects: 114
Study 21794128 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Network Test (ANT) in ADHD subgroup with affective fluctuations (n = 22)
Number of subjects: 114
Study 21794128 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Network Test (ANT) in ADHD subgroup without affective fluctuations
Number of subjects: 114
Study 19326695 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 40 sunscreen cream containing ecamsule 3%, octocrylene 10%, avobenzone 2%, and titanium dioxide 5% (tetrad)
Number of subjects: 144
Study 19326695 — intervention group
Group type: COMPARATOR
Intervention: Ecamsule-deprived cream (triad-E)
Number of subjects: 144
Study 19326695 — intervention group
Group type: COMPARATOR
Intervention: Avobenzone-deprived cream (triad-A)
Number of subjects: 144
Study 16957433 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retapamulin ointment, 1% for 5 days twice daily
Number of subjects: 1904
Study 16957433 — intervention group
Group type: COMPARATOR
Intervention: Oral cephalexin, 500 mg twice daily for 10 days
Number of subjects: 1904
Study 15016485 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536
Study 11703421 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MG)
Number of subjects: 26
Study 11703421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PG)
Number of subjects: 26
Study 9155314 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency contracting intervention with nurses
Number of subjects: 0
Study 9155314 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of adherence to nutrition recommendations
Number of subjects: 0
Study 9155314 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of adherence to nutrition recommendations
Number of subjects: 0
Study 7536071 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (LD-CY, 1500 mg/m2) plus cisplatin (CDDP) 100 mg/m2 (OvCa) or epirubicin (EPR) 120 mg/m2 (BrCa) plus recombinant human G-CSF (rhG-CSF)
Number of subjects: 12
Study 7536071 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDC) with carboplatin 1200 mg/m2, etoposide 900 mg/m2 and melphalan 100 mg/m2 with reinfusion of PBSC
Number of subjects: 12
Study 3148298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of human milk since the 15th day of TPN
Number of subjects: 30
Study 3148298 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole since the 15th day
Number of subjects: 30
Study 3148298 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral antibiotic therapy for septicemia since the 1st day
Number of subjects: 30
Study 3148298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 28736267 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma tocopherol (γT) 1200 mg daily for 14 days
Number of subjects: 15
Study 28736267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27591457 — intervention group
Group type: EXPERIMENTAL
Intervention: Active warming from a thermal gown 30min before spinal anesthesia and during surgery (Go, n=20)
Number of subjects: 40
Study 27591457 — intervention group
Group type: COMPARATOR
Intervention: No active warming at any time (Ct, n=20)
Number of subjects: 40
Study 24712568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 24712568 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg T enanthate
Number of subjects: 71
Study 24712568 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.25 mg T enanthate
Number of subjects: 71
Study 24712568 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg T enanthate
Number of subjects: 71
Study 24712568 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg T enanthate
Number of subjects: 71
Study 24060060 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Classroom Management (IY-TCM) program
Number of subjects: 107
Study 21518073 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=85) received an educational session, dental supplies, and scheduled oral care appointment.
Number of subjects: 170
Study 21518073 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=85) did not receive the intervention.
Number of subjects: 170
Study 18442447 — intervention group
Group type: EXPERIMENTAL
Intervention: Grouped dot displays
Number of subjects: 140
Study 18442447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersed dot displays
Number of subjects: 140
Study 16832795 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized telephone counseling and individually tailored materials, including motivational goal-setting session, three sets of tailored materials, three follow-up counseling sessions, and linkages to free screening programs.
Number of subjects: 494
Study 16832795 — intervention group
Group type: COMPARATOR
Intervention: Usual care arm, which included physician suggestion to notify family members about melanoma diagnosis and encourage screening.
Number of subjects: 494
Study 12833110 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Level (PAL)
Number of subjects: 1064
Study 12833110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary energy intake
Number of subjects: 1064
Study 12833110 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 1064
Study 12833110 — intervention group
Group type: COMPARATOR
Intervention: Dietary Calcium intake
Number of subjects: 1064
Study 11469292 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser (10.600 nm)
Number of subjects: 66
Study 11469292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1.064 nm)
Number of subjects: 66
Study 11469292 — intervention group
Group type: EXPERIMENTAL
Intervention: ArF excimer laser (193 nm)
Number of subjects: 66
Study 9034644 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 20
Study 9034644 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin
Number of subjects: 20
Study 9034644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonovine
Number of subjects: 20
Study 9034644 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine and Serotonin
Number of subjects: 20
Study 9034644 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin but not Acetylcholine
Number of subjects: 20
Study 9034644 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine but not Serotonin
Number of subjects: 20
Study 8366188 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 2.5 mg
Number of subjects: 10
Study 8366188 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 5.0 mg
Number of subjects: 10
Study 8366188 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine 10.0 mg
Number of subjects: 10
Study 8366188 — intervention group
Group type: COMPARATOR
Intervention: famotidine 0.5 mg
Number of subjects: 10
Study 8366188 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 2901062 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate (0.5%)
Number of subjects: 60
Study 2901062 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 60
Study 30276974 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with paclitaxel and cisplatin
Number of subjects: 486
Study 30276974 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy with intensity-modulated radiation of 50 Gy
Number of subjects: 486
Study 30276974 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 486
Study 27483185 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer sex intervention delivered via automated mobile phone messaging over 12 months
Number of subjects: 200
Study 27483185 — intervention group
Group type: COMPARATOR
Intervention: Monthly text message checking contact details (Control)
Number of subjects: 200
Study 27483185 — intervention group
Group type: EXPERIMENTAL
Intervention: Safer sex intervention delivered via automated mobile phone messaging
Number of subjects: 200
Study 24091560 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water nasal irrigation
Number of subjects: 64
Study 24091560 — intervention group
Group type: COMPARATOR
Intervention: Non-tap water nasal irrigation
Number of subjects: 64
Study 23404880 — intervention group
Group type: EXPERIMENTAL
Intervention: Layered stimulus and response training (LSRT)
Number of subjects: 24
Study 23404880 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery (MI) practice
Number of subjects: 24
Study 23404880 — intervention group
Group type: COMPARATOR
Intervention: Visual imagery (VI) practice
Number of subjects: 24
Study 15829782 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injection into the mid-belly of the muscle bulks (distal group)
Number of subjects: 19
Study 15829782 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin A injection into the proximal part of both heads of the gastrocnemius (proximal group)
Number of subjects: 19
Study 12810404 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCT diet (14 g of MLCT containing 1.7 g MCFA daily at breakfast for 12 weeks)
Number of subjects: 82
Study 12810404 — intervention group
Group type: COMPARATOR
Intervention: LCT diet (control group)
Number of subjects: 82
Study 12810404 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCT diet
Number of subjects: 82
Study 9795914 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg lamivudine once daily
Number of subjects: 51
Study 9795914 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg lamivudine once daily
Number of subjects: 51
Study 9795914 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg lamivudine once daily
Number of subjects: 51
Study 8535683 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral hyperthermia (TUH)
Number of subjects: 200
Study 8535683 — intervention group
Group type: COMPARATOR
Intervention: Transurethral sham (TUS)
Number of subjects: 200
Study 8535683 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal hyperthermia (TRH)
Number of subjects: 200
Study 8535683 — intervention group
Group type: COMPARATOR
Intervention: Transrectal sham (TRS)
Number of subjects: 200
Study 2227221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine 10 mg twice daily
Number of subjects: 26
Study 2227221 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg three times daily
Number of subjects: 26
Study 83330 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid smoking (overt aversion)
Number of subjects: 60
Study 83330 — intervention group
Group type: EXPERIMENTAL
Intervention: Covert sensitization (symbolic aversion)
Number of subjects: 60
Study 83330 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rapid smoking and covert sensitization
Number of subjects: 60
Study 83330 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 31511232 — intervention group
Group type: EXPERIMENTAL
Intervention: Running programme intervention
Number of subjects: 3040
Study 31511232 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoe-related intervention
Number of subjects: 3040
Study 29492784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 26
Study 29492784 — intervention group
Group type: COMPARATOR
Intervention: Support group
Number of subjects: 26
Study 27895298 — intervention group
Group type: EXPERIMENTAL
Intervention: Right insular involvement
Number of subjects: 2099
Study 27895298 — intervention group
Group type: COMPARATOR
Intervention: Left insular involvement
Number of subjects: 2099
Study 27895298 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild/moderate strokes with right insular involvement
Number of subjects: 2099
Study 27895298 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe strokes with right insular involvement
Number of subjects: 2099
Study 24172309 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g MCT oil/d
Number of subjects: 28
Study 24172309 — intervention group
Group type: COMPARATOR
Intervention: 20 g corn oil/d
Number of subjects: 28
Study 22020134 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid-rich fish oil (1g)
Number of subjects: 65
Study 22020134 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid-rich fish oil (2g)
Number of subjects: 65
Study 22020134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 65
Study 20434660 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction
Number of subjects: 113
Study 20434660 — intervention group
Group type: COMPARATOR
Intervention: Double-bundle ACL reconstruction
Number of subjects: 113
Study 19014838 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of clarithromycin extended-release 500-mg tablets under fasting conditions
Number of subjects: 38
Study 19014838 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of clarithromycin extended-release 500-mg tablets under fasting conditions
Number of subjects: 38
Study 19014838 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of clarithromycin extended-release 500-mg tablets under fed conditions
Number of subjects: 38
Study 19014838 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of clarithromycin extended-release 500-mg tablets under fed conditions
Number of subjects: 38
Study 16047460 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg twice daily
Number of subjects: 10
Study 16047460 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 20 mg twice daily
Number of subjects: 10
Study 16047460 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 10
Study 16047460 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily
Number of subjects: 10
Study 12518705 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone
Number of subjects: 18
Study 12518705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio‐Oss
Number of subjects: 18
Study 12518705 — intervention group
Group type: COMPARATOR
Intervention: Control (nonaugmented sites)
Number of subjects: 18
Study 10363292 — intervention group
Group type: EXPERIMENTAL
Intervention: BASC Parent Rating Scale (PRS) 6‐11, authorized Spanish version
Number of subjects: 120
Study 10363292 — intervention group
Group type: EXPERIMENTAL
Intervention: BASC PRS (6‐11)
Number of subjects: 120
Study 10363292 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis
Number of subjects: 120
Study 10363292 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample assessment
Number of subjects: 120
Study 9381885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal application of 'Zhlemik' on a tampon
Number of subjects: 40
Study 9381885 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal suppositories of 'Zhlemik'
Number of subjects: 40
Study 2210463 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily)
Number of subjects: 270
Study 2210463 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (400 mg four times daily)
Number of subjects: 270
Study 7004258 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 60
Study 7004258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31751759 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) for hazelnut allergy for at least 6 months.
Number of subjects: 100
Study 31751759 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline eliciting dose of hazelnut protein was 106 mg (IQR, 51-249); after 6 months of OIT, it increased to 523 mg (IQR, 190-1635) (P < .0001).
Number of subjects: 100
Study 31751759 — intervention group
Group type: EXPERIMENTAL
Intervention: OIT
Number of subjects: 100
Study 30341774 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical regorafenib (25 μl, 30 mg ml‐1) three times a day for 12 weeks
Number of subjects: 51
Study 30341774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular treatment‐emergent adverse events (TEAEs)
Number of subjects: 51
Study 30341774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue treatment (intravitreal ranibizumab)
Number of subjects: 51
Study 28811738 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention with partner enrollment
Number of subjects: 238
Study 28811738 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for obese participants
Number of subjects: 238
Study 28811738 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention for morbidly obese participants
Number of subjects: 238
Study 25802037 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) for 12 weeks (three weekly sessions lasting 38 min with ≈ 16 min at 85‐90% of VO2peak)
Number of subjects: 70
Study 25802037 — intervention group
Group type: COMPARATOR
Intervention: Low energy diet (LED, 800‐1000 kcal/day) for 12 weeks
Number of subjects: 70
Study 25802037 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT)
Number of subjects: 70
Study 25802037 — intervention group
Group type: COMPARATOR
Intervention: Low energy diet (LED)
Number of subjects: 70
Study 25802037 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AIT and LED
Number of subjects: 70
Study 24058667 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert video game players (VGPs)
Number of subjects: 31
Study 24058667 — intervention group
Group type: COMPARATOR
Intervention: Non-video game players (non-VGPs)
Number of subjects: 31